Sage Journals: Discover world-class research

Abstract

In August 2015, the US Food and Drug Administration approved the production of Addyi (flibanserin), a pharmaceutical tablet for premenopausal women distressed by a lack of sexual desire. During clinical trials, reports from research participants revealed minimal efficacy: an estimated 0.8 increase in ‘satisfying sexual events’ per month. This article explores the emergence of Addyi as a case study of how this technique produces a particular subject of pharmaceutical knowledge. It examines the pharmaceutical tablet as a technique for the management of sexual appetite. I consider the significance of the act of pharmaceutical ingestion on the embodied subjectivity of the consumer and the chemical constitution of the human body.

Keywords

Addyi desire pharmaceuticals sexuality women

Get full access to this article

View all access options for this article.

References

AbbVie (2017) AndroGel. Available at: https://www.androgel.com/ (accessed 16 April 2017).

Addyi (2015a) What is Addyi? Available at: https://www.addyi.com/ (accessed 16 November 2016).

Addyi (2015b) Decreased sexual desire screener. Available at: http://www.addyi.com/Portals/37/dsds-screener.pdf (accessed 4 November 2016).

APA (2013) The Diagnostic and Statistical Manual of Mental Disorders, Arlington, VA: American Psychiatric Association.

Ashline

McKay

(2017) Content analysis of patient voices at the FDA’s ‘Female sexual dysfunction patient-focused drug development public meeting’. Sexuality & Culture 21(2): 569–592.

Berg M and Mol A (eds) (1998) Differences in Medicine: Unraveling Practices, Techniques and Bodies. Durham, NC: Duke University Press.

Berlant

Warner

(1998) Sex in public. Critical Inquiry 24(2): 547–566.

Cacchioni

(2014) Sexuopharmaceuticals. In: Whelehan

Bolin

(eds) The International Encyclopedia of Human Sexuality, Chichester: Wiley Blackwell, pp. 1305–1309.

Cacchioni

(2015) Big Pharma, Women and the Labour of Love, Toronto: University of Toronto Press.

10.

Clayton

Dennerstein

Pyke

et al. (2010) Flibanserin: A potential treatment for hypoactive sexual desire disorder in premenopausal women. Women’s Health 6(5): 639–653.

11.

Drucker

(2014) The Machines of Sex Research: Technology and the Politics of Identity, 1945–1985, Dordrecht: Springer.

12.

Edelman

(2004) No Future: Queer Theory and the Death Drive, Durham, NC: Duke University Press.

13.

Fahs B (2016) Slippery desire: Women’s accounts of their vaginal lubrication. Feminism & Psychology. Online first. DOI: 10.1177/0959353516674239.

14.

Fishman

(2004) Manufacturing desire: The commodification of female sexual dysfunction. Social Studies of Science 34(2): 187–218.

15.

Flore

(2016) The problem of sexual imbalance and techniques of the self in the Diagnostic and Statistical Manual of Mental Disorders. History of Psychiatry 27(3): 320–335.

16.

Foucault

(2003) Society Must Be Defended: Lectures at the Collège de France, 1975–76, London: Penguin Books.

17.

Gelez

Clement

Compagnie

et al. (2013) Brain neuronal activation induced by flibanserin treatment in female rats. Psychopharmacology 230(4): 639–652.

18.

Georgiadis

Kringelbach

(2012) The human sexual response cycle: Brain imaging evidence linking sex to other pleasures. Progress in Neurobiology 98(1): 49–81.

19.

Ghorayshi A (2015) How big pharma used feminism to get the ‘female Viagra’ approved. Available at: www.buzzfeed.com/azeenghorayashi/fda-approves-flibanserin (accessed 15 October 2015).

20.

Halberstam

(2005) In a Queer Time and Place: Transgender Bodies, Subcultural Lives, New York: New York University Press.

21.

Haraway

(1991) Simians, Cyborgs, and Women: The Reinvention of Nature, New York: Taylor & Francis.

22.

Helfand C (2016) Scripts sink for Valeant’s troubled female libido drug in wake of rep cuts. Available at: http://www.fiercepharma.com/marketing/scripts-sink-for-valeant-s-troubled-female-libido-drug-wake-rep-cuts (accessed 2 October 2015).

23.

Hitt J (2000) The second sexual revolution. Available at: http://www.nytimes.com/2000/02/20/magazine/the-second-sexual-revolution.html?pagewanted=all (accessed 2 October 2015).

24.

Johnson

Jr (2010) ‘Just getting off’: The inseparability of ejaculation and hegemonic masculinity. The Journal of Men’s Studies 18(3): 238–248.

25.

Laan E and Tiefer L (2014) ‘Pink Viagra’: The sham drug idea of the year. Available at: http://www.latimes.com/opinion/op-ed/la-oe-laan-tiefer-pink-viagra-20141114-story.html (accessed 13 November 2015).

26.

Lamm

Couzens

(1998) The Virility Solution: Everything You Need to Know about Viagra, the Potency Pill that Can Restore and Enhance Male Sexuality, New York: Fireside Books.

27.

Layton

Kim

Caleb Alexander

et al. (2017) Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009–2013. Journal of the American Medical Association 317(11): 1159–1166.

28.

Loe

(2004) The Rise of Viagra: How the Little Blue Pill Changed Sex in America, New York: New York University Press.

29.

Lucke J (2015) A sexually satisfying event for women, or just a new identity for an old antidepressant. Available at: https://theconversation.com/a-sexually-satisfying-event-for-women-or-just-a-new-identity-for-an-old-antidepressant-42734 (accessed 6 June 2015).

30.

Marshall

(2002) ‘Hard science’: Gendered constructions of sexual dysfunction in the ‘Viagra age’. Sexualities 5(2): 131–158.

31.

Marshall

(2008) Older men and sexual health: Post-Viagra views on changes in function. Generations 32(1): 21–27.

32.

Marshall

(2009) Sexual medicine, sexual bodies and the ‘pharmaceutical imagination’. Science as Culture 18(2): 133–149.

33.

Martin

(2006) The pharmaceutical person. Biosocieties 1(3): 273–288.

34.

McLaren

(2007) Impotence: A Cultural History, Chicago: University of Chicago Press.

35.

Mintzes B and Tiefer L (2015) We shouldn’t push dubious ‘pink Viagra’ pills on women and call it emancipation. Available at: https://www.theguardian.com/commentisfree/2015/jun/05/women-sex-viagra-flibanserin-fda-research (accessed 6 June 2015).

36.

Moynihan

(2003) The making of a disease: Female sexual dysfunction. British Medical Journal 326(7379): 326–345.

37.

Potts

(2005) Cyborg masculinity in the Viagra era. Sexualities, Evolution and Gender 7(1): 3–16.

38.

Preciado

(2013) Testo Junkie: Sex, Drugs, and Biopolitics in the Pharmacopornographic Era, New York: The Feminist Press.

39.

Race

(2009) Pleasure Consuming Medicine: The Queer Politics of Drugs, Durham, NC: Duke University Press.

40.

Ramsey L (2015) $1 billion deal will help bring controversial ‘female Viagra’ drug to market. Available at: http://www.businessinsider.com.au/valeant-acquires-sprout-pharma-for-1-billion-2015-8 (accessed 2 October 2015).

41.

Rose

(1996) Inventing Our Selves: Psychology, Power, and Personhood, Cambridge: Cambridge University Press.

42.

Rose

(2007a) The Politics of Life Itself: Biomedicine, Power, and Subjectivity in the Twenty-First Century, Princeton, NJ: Princeton University Press.

43.

Rose

(2007b) Beyond medicalisation. The Lancet 369(9562): 700–702.

44.

Rose

Abi-Rached

(2013) Neuro: The New Brain Sciences and the Management of the Mind, Princeton, NJ: Princeton University Press.

45.

Segal

(2012) The sexualization of the medical. Journal of Sex Research 49(4): 369–378.

46.

Segal

(2015) The rhetoric of female sexual dysfunction: Faux feminism and the FDA. Canadian Medical Association Journal 187(12): 915–916.

47.

Sprout (2015) Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women NDA 022526, Advisory Committee Briefing Document, 4 June. Sprout Pharmaceuticals.

48.

Stoléru

Fonteille

Cornélis

et al. (2012) Functional neuroimaging studies of sexual arousal and orgasm in healthy men and women: A review and meta-analysis. Neuroscience and Biobehavioral Reviews 36(6): 1481–1509.

49.

Tiefer

(1995) Sex is not a Natural Act & Other Essays, Boulder, CO: Westview Press.

50.

Tiefer

(1996) The medicalization of sexuality: Conceptual, normative and professional issues. Annual Review of Sex Research 7(1): 252–282.

51.

Tiefer

(2002a) Arriving at a ‘new view’ of women’s sexual problems: Background, theory and activism. Women & Therapy 24(1–2): 63–98.

52.

Tiefer

(2002b) Pleasure, medicalization and the tyranny of the natural. Siecus Report 30(4): 23–26.

53.

Tiefer

(2006) The Viagra phenomenon. Sexualities 9(3): 273–294.

54.

Velten

Scholten

Graham

et al. (2016) Investigating female sexual concordance: Do sexual excitation and sexual inhibition moderate the agreement of genital and subjective sexual arousal in women? Archives of Sexual Behavior 45(8): 1957–1971.

55.

Viagra (2015) Learning: How does Viagra work? Available at: https://www.viagra.com/learning/how-does-viagra-work (accessed 5 November 2015).

56.

Weintraub A (2015) Why all those testosterone ads constitute disease mongering. Available at: https://www.forbes.com/sites/arleneweintraub/2015/03/24/why-all-those-testosterone-ads-constitute-disease-mongering/#437f72aa5853 (accessed 16 April 2017).

57.

Wilson

(2015) Gut Feminism, Durham, NC: Duke University Press.